Abstract：
Noninvasive and minimally invasive preimplantation genetic testing for aneuploidy (PGT-A) is a tool that may one day become the gold standard for embryonic chromosomal screening. Investigations on this topic have ranged from studying the culture media of embryos to the fluid inside the blastocoel, all in an attempt to find a reliable source of DNA without the need to biopsy the embryo. There is great interest across the board, both from those for and against biopsy, in a reliable test process that would give the patient and provider the same information possible from a biopsy without the risk. We aim to explore the current available research to better understand the utility and accuracy of PGT-A with these new sampling techniques. General concordance rates in comparison with biopsy-based PGT-A are promising, but it is clear that additional research and understanding are needed before adopting noninvasive and minimally invasive PGT-A as a widely used tool with strong clinical utility.
摘要：
非侵入性/微创PGT-A是有一天可能成为胚胎染色体筛查的黄金标准的工具。关于这个主题的研究范围从研究胚胎的培养基到胚层内部的液体，所有这些都是为了寻找可靠的DNA来源，而不需要对胚胎进行活检。大家都有很大的兴趣,无论是支持还是反对活检，对于一个可靠的测试过程，将给患者和提供者相同的信息可能从活检没有风险。我们的目标是探索当前可用的研究，以更好地了解使用这些新的采样技术的PGT-A的实用性和准确性。与基于活检的PGT-A相比，总体符合率是有希望的，但很明显,在采用非侵入性/微创性PGT-A作为具有强大临床实用性的广泛使用的工具之前,还需要更多的研究和理解.
